Clinical Trial Update: Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating elotuzumab plus lenalidomide for serologic relapse/progression on lenalidomide in multiple myeloma; study terminated with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elotuzumab (elotuzumab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2022-04-14